Chiltern has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.
 
With staff based in Japan, Korea and Southeast Asia, IDA has offers expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will allow Chiltern to offer optimal approaches for integrating Japan and Asia into global drug development. The acquisition also opens opportunities for Japanese companies to enter a wider market leveraging Chiltern’s global services and connections.
 
“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” said Jim Esinhart, Ph.D., Chiltern chief executive officer. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”
 
IDA will do business as a wholly owned subsidiary of Chiltern and be renamed IDA, a Chiltern Company. As a part of this agreement, IDA’s founder and chief executive officer, John Winebarger, will continue to lead IDA. Mr. Winebarger has more than 30 years of experience working in Japan and will join Chiltern’s leadership team.